Roche Promotes Lung Cancer Therapies, ArQule

Roche drugs point to personalized lung cancer care

(Reuters) - Roche's experimental drug MetMab and its established product Tarceva showed impressive results in lung cancer trials on Saturday, highlighting how treating the disease is becoming much more focused.


Cancer experts meeting Milan said personalized treatment, first seen in breast cancer, was now emerging as a major theme in lung cancer. The shift could reduce the use of less targeted drugs, including Roche's own top-selling Avastin.

Is ArQule The Next Dendreon?

Image via Wikipedia This stock has been on my radar for a couple of months. Arqule could be the next Dendreon. It is a cash cow and needs a little more clinical trial data before I pull the trigger but I will continue to watch this stock. I will keep you up to date if anything changes. Currently AQ197 is entering Phase III clinical trials for non-small cell lung cancer with Japanese partner Daiichi Sankyo.

ArQule:  (ARQL)
Daiichi Sankyo:  (Tokyo: 4568)

ArQule's sky-high, but there still could be upside

By Val Brickates Kennedy, MarketWatch June 4, 2010